Vida Ventures

Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations

Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Tectonic Therapeutic Launches with $80 Million Series A Financing to Transform the Discovery of Novel G-Protein Coupled Receptor (GPCR)-Targeted Therapies

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors

InnoSkel Launches with $20 Million Series A Financing

Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

• Fierce Biotech Article – January 23, 2023 read more

Fierce Biotech Article – January 23, 2023

• Affini-T Therapeutics to Present at the 41st Annual J
• P
• Morgan Healthcare Conference read more

Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

• AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy read more

Hold ourselves and our partners to the highest standards Take initiative to turn ideas into reality Drive breakthrough science into medicines Recognize that the best can come from anywhere Partner to create something grander than the parts Embrace each endeavor with an open mind Make a meaningful difference in patients’ lives © 2023 Vida Ventures, LLC